H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CAPR stock, giving a Buy rating on September 15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Capricor Therapeutics’ ongoing progress and potential in addressing cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). The company is actively engaged in discussions with the FDA regarding the regulatory path for deramiocel, their lead therapeutic candidate. Despite some delays, the dialogue with the FDA remains constructive, and there is optimism surrounding potential adjustments to the HOPE-3 trial’s primary endpoint, which could significantly impact the approval process.
Furthermore, Capricor’s response to the FDA’s Complete Response Letter (CRL) has provided additional clarity and transparency. The company’s adjustments to their statistical strategy in the HOPE-2 study demonstrated significant efficacy, which was initially overlooked. Additionally, the majority of cardiac parameters in the study favored deramiocel, suggesting a positive impact on cardiac tissue. These factors, along with the resolution of certain manufacturing deficiencies, contribute to Pantginis’s positive outlook on Capricor’s stock.
In another report released on September 15, B.Riley Financial also maintained a Buy rating on the stock with a $21.00 price target.